Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study (Q33969308)

30 July 2017

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study (English)

1 reference

30 July 2017

0 references

1 reference

Igor Bondarenko

3

0 references

Rodryg Ramlau

object named as

Rodryg Ramlau

12

0 references

author name string

Kenneth J O'Byrne

1

1 reference

30 July 2017

Ulrich Gatzemeier

2

1 reference

30 July 2017

Carlos Barrios

4

1 reference

30 July 2017

Corinna Eschbach

5

1 reference

30 July 2017

Uwe M Martens

6

1 reference

30 July 2017

Yevhen Hotko

7

1 reference

30 July 2017

Cornelius Kortsik

8

1 reference

30 July 2017

Luis Paz-Ares

9

1 reference

30 July 2017

Jose R Pereira

10

1 reference

30 July 2017

Joachim von Pawel

11

1 reference

30 July 2017

Jae-Kyung Roh

13

1 reference

30 July 2017

Chih-Teng Yu

14

1 reference

30 July 2017

Christopher Stroh

15

1 reference

30 July 2017

Ilhan Celik

16

1 reference

30 July 2017

Armin Schueler

17

1 reference

30 July 2017

Robert Pirker

18

1 reference

30 July 2017

22 July 2011

1 reference

Lancet Oncology Commission

30 July 2017

1 reference

30 July 2017

12

1 reference

30 July 2017

8

1 reference

30 July 2017

795-805

1 reference

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

PTEN and the PI3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

The cetuximab experience: developing predictive biomarkers in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

The new lung cancer staging system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

KRAS mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

If histology matters...

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Lung cancer in never smokers--a different disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Lung cancer in never smokers: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970189-9

7 January 2021

10.1016/S1470-2045(11)70189-9

Identifiers

DOI

1 reference

release_q73cgu742ne5jd466fnc3mcnci

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q73cgu742ne5jd466fnc3mcnci

24 November 2022

mapped directly with Wikidata item

1 reference